Is Maze Therapeutics, Inc. (MAZE) a Buy, Sell, or Hold?
NASDAQ : MAZE
Maze Therapeutics, Inc.
$28.69 USD
$1.01 (3.65%)
- Volume
- 265.61K
- Average Volume
- 609.54K
- Market Capitalization
- $1.59B
- P/E Ratio
- -10.43
- Dividend Yield
- 0.00%
- Price Target
- $80.50
- Year High
- $53.65
- Year Low
- $12.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $17.88
Company Overview
NASDAQ
Jason Coloma
Biotechnology
Healthcare
MAZE
141
US
USD
Liquidity Metrics
0.18
17.88
17.88
9.36
0.00
Sales & Valuation
-$
79.39
4.53
-13.00
-2.27
Profitability
-$3.05
-$131.12M
-612.71%
-612.71%
-36.63%
-29.20%
P/E Metrics
-10.43
0.01
0.01
Analyst Price Target & Rating
$80.50
$97.00
$64.00
2/5
6 Analysts
-64.36%
Financial Health Scores
10.19
3/9
$358.54M
$419.71M
$78.01M
-$121.68M
Key Metrics (TTM)
$1.39B
69.72
-11.67
17.88
-36.63%
-33.24%
-8.21%
-7.97%
-555 days
Company Executives
| Name | Title |
|---|---|
| Misbah Tahir | CFO & Principal Accounting Officer |
| Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations |
| Winston Tse | Senior Vice President of Drug Discovery |
| Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain |
| Maarten Hoek | Senior Vice President of Research |
| Matt Krause | Senior Vice President of Human Resources |
| Amy Bachrodt | Senior Vice President of Finance |
| Courtney J. Phillips | General Counsel & Corporate Secretary |
| Susan Limb | Senior Vice President of Clinical Development |
| Harold S. Bernstein | President of Research & Development and Chief Medical Officer |
| Atul Dandekar | Chief Strategy & Business Officer |
| Jason V. Coloma | Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC ... 13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
2026-07-21 10:55:15
The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
2026-06-29 08:46:01
This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.
2026-06-10 11:42:11
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
2026-05-27 07:03:06
SOUTH SAN FRANCISCO, Calif. , May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph. D. , chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences: 2026 Jefferies Global Healthcare Conference in New York; presentation on Wednesday, June 3, 2026, at 3:45 p.
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
2026-05-27 07:03:00
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences:
2026-05-17 14:53:24
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
2026-05-12 18:16:10
Maze Therapeutics, Inc. (MAZE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.15 per share a year ago.
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
2026-05-12 16:01:00
Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027 Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026 Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, highlighting recent progress and business updates.
Frequently Asked Questions
-
What is the current Maze Therapeutics, Inc. (MAZE) stock price?
-
Maze Therapeutics, Inc.(NASDAQ:MAZE) stock price is $28.69 in the last trading session. During the trading session, MAZE stock reached the peak price of $53.65 while $12.81 was the lowest point it dropped to. The percentage change in MAZE stock occurred in the recent session was 3.65% while the dollar amount for the price change in MAZE stock was $1.01.
-
MAZE's industry and sector of operation?
-
The NASDAQ listed MAZE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MAZE?
-
Misbah Tahir | CFO & Principal Accounting Officer
Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations
Winston Tse | Senior Vice President of Drug Discovery
Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain
Maarten Hoek | Senior Vice President of Research -
How many employees does MAZE have?
-
Number of MAZE employees currently stands at 141. MAZE operates from 171 Oyster Point Blvd, South San Francisco, CA 94080, US.
-
Link for MAZE official website?
-
Official Website of MAZE is: https://www.mazetx.com
-
How do I contact MAZE?
-
MAZE could be contacted at phone #650 850 5070 and can also be accessed through its website. MAZE operates from 171 Oyster Point Blvd, South San Francisco, CA 94080, US.
-
How many shares of MAZE are traded daily?
-
The average number of MAZE shares traded daily for last 3 months was 609.54K.
-
What is the market cap of MAZE currently?
-
The market value of MAZE currently stands at $1.59B with its latest stock price at $28.69